Adipokines regulate systemic insulin sensitivity in accordance to existing energy reserves

Medical Hypotheses

Volumn 69, Issue 1, 2007, Pages 161-165

  Huypens, P ^a  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; ADIPOCYTOKINE; ADIPONECTIN; INSULIN RECEPTOR SUBSTRATE 1; LEPTIN; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; TROGLITAZONE;

ADIPOSE TISSUE; ARTICLE; BODY MASS; DOSE RESPONSE; DRUG MECHANISM; ENERGY RESOURCE; ENZYME ACTIVITY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION;

ADIPONECTIN; ADIPOSE TISSUE; ENERGY METABOLISM; HUMANS; INSULIN RESISTANCE; LEPTIN; MODELS, BIOLOGICAL; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 34247579096     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.10.053     Document Type: Article

References (62)

1. Schwartz M.W., and Porte Jr. D. Diabetes, obesity, and the brain. Science 307 (2005) 375-379
2. Covey S.D., Wideman R.D., McDonald C., Unniappan S., Huynh F., Asadi A., et al. The pancreatic beta cell is a key site for mediating the effects of leptin on glucose homeostasis. Cell Metab 4 (2006) 291-302
3. Kieffer T.J., and Habener J.F. The adipoinsular axis: effects of leptin on pancreatic beta-cells. Am J Physiol 278 (2000) E1-E14
4. Perez C., Fernandez-Galaz C., Fernandez-Agullo T., Arribas C., Andres A., Ros M., et al. Leptin impairs insulin signaling in rat adipocytes. Diabetes 53 (2004) 347-353
5. Suzuki R., Tobe K., Aoyama M., Sakamoto K., Ohsugi M., Kamei N., et al. Expression of DGAT2 in white adipose tissue is regulated by central leptin action. J Biol Chem 280 (2005) 3331-3337
6. Muller G., Ertl J., Gerl M., and Preibisch G. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J Biol Chem 272 (1997) 10585-10593
7. Ceddia R.B., William Jr. W.N., Lima F.B., and Curi R. Leptin inhibits insulin-stimulated incorporation of glucose into lipids and stimulates glucose decarboxylation in isolated rat adipocytes. J Endocrinol 158 (1998) R7-R9
8. Hu E., Liang P., and Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271 (1996) 10697-10703
9. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
10. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001) 1930-1935
11. Berg A.H., Combs T.P., Du X., Brownlee M., and Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7 (2001) 947-953
12. Fu Y., Luo N., Klein R.L., and Garvey W.T. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res 46 (2005) 1369-1379
13. Wu X., Motoshima H., Mahadev K., Stalker T.J., Scalia R., and Goldstein B.J. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 52 (2003) 1355-1363
14. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 (2002) 1288-1295
15. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 (2001) 941-946
16. Seo J.B., Moon H.M., Noh M.J., Lee Y.S., Jeong H.W., Yoo E.J., et al. Adipocyte determination- and differentiation-dependent factor 1 (ADD1)/sterol regulatory element binding protein 1c (SREBP1c) regulates mouse adiponectin expression. J Biol Chem 279 (2004) 22108-22117
17. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (2001) 2094-2099
18. Iwaki M., Matsuda M., Maeda N., Funahashi T., Matsuzawa Y., Makishima M., et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52 (2003) 1655-1663
19. Yang W.S., Lee W.J., Funahashi T., Tanaka S., Matsuzawa Y., Chao C.L., et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86 (2001) 3815-3819
20. Yu J.G., Javorschi S., Hevener A.L., Kruszynska Y.T., Norman R.A., Sinha M., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51 (2002) 2968-2974
21. Combs T.P., Wagner J.A., Berger J., Doebber T., Wang W.J., Zhang B.B., et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPAR gamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143 (2002) 998-1007
22. Ott V., Fasshauer M., Dalski A., Meier B., Perwitz N., Klein H.H., et al. Direct peripheral effects of ghrelin include suppression of adiponectin expression. Horm Metab Res 34 (2002) 640-645
23. Huypens P., Quartier E., Pipeleers D., and Van de Casteele M. Metformin reduces adiponectin protein expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase. Eur J Pharmacol 518 (2005) 90-95
24. Lihn A.S., Jessen N., Pedersen S.B., Lund S., and Richelsen B. AICAR stimulates adiponectin and inhibits cytokines in adipose tissue. Biochem Biophys Res Commun 316 (2004) 853-858
25. Fain J.N., Bahouth S.W., and Madan A.K. TNFalpha release by the nonfat cells of human adipose tissue. Int J Obes Relat Metab Disord 28 4 (2004) 616-622
26. Jhun B.S., Jin Q., Oh Y.T., Kim S.S., Kong Y., Cho Y.H., et al. 5-Aminoimidazole-4-carboxamide riboside suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of phosphatidylinositol 3-kinase/Akt activation in RAW 264.7 murine macrophages. Biochem Biophys Res Commun 318 (2004) 372-380
27. Fasshauer M., Klein J., Neumann S., Eszlinger M., and Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 290 (2002) 1084-1089
28. Barth N., Langmann T., Scholmerich J., Schmitz G., and Schaffler A. Identification of regulatory elements in the human adipose most abundant gene transcript-1 (apM-1) promoter: role of SP1/SP3 and TNF-alpha as regulatory pathways. Diabetologia 45 (2002) 1425-1433
29. Ruan H., Miles P.D., Ladd C.M., Ross K., Golub T.R., Olefsky J.M., et al. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes 51 (2002) 3176-3188
30. Phillips S.A., Ciaraldi T.P., Kong A.P.S., Bandukwala R., Aroda V., Carter L., et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 52 (2003) 667-674
31. Tiikkainen M., Hakkinen A.M., Korsheninnikova E., Nyman T., Makimattila S., and Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53 (2004) 2169-2176
32. Rosenstock J., Rood J., Cobitz A., Biswas N., Chou H., and Garber A. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab 8 6 (2006) 650-660
33. Rosenstock J., Rood J., Cobitz A., Huang C., and Garber A. Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control. Diabetes Obes Metab 8 6 (2006) 643-649
34. Seufert J. A fixed-dose combination of pioglitazone and metformin: a promising alternative in metabolic control. Curr Med Res Opin 22 Suppl. 2 (2006) 39-48
35. Bailey C.J. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 7 (2005) 675-691
36. Stumvoll M. Control of glycaemia: from molecules to men. Minkowski Lecture 2003. Diabetologia 2004;47:770-81.
37. Smith U. Impaired ('diabetic') insulin signaling and action occur in fat cells long before glucose intolerance-is insulin resistance initiated in the adipose tissue?. Int J Obes Relat Metab Disord 26 (2002) 897-904
38. Smith U., Axelsen M., Carvalho E., Eliasson B., Jansson P.A., and Wesslau C. Insulin signaling and action in fat cells: associations with insulin resistance and type 2 diabetes. Ann N Y Acad Sci 892 (1999) 119-126
39. Ning K., Miller L.C., Laidlaw H.A., Burgess L.A., Perera N.M., Downes C.P., et al. A novel leptin signalling pathway via PTEN inhibition in hypothalamic cell lines and pancreatic beta-cells. EMBO J 25 (2006) 2377-2387
40. Maffei M., Halaas J., Ravussin E., Pratley R.E., Lee G.H., Zhang Y., et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1 (1995) 1155-1161
41. Frederich R.C., Hamann A., Anderson S., Lollmann B., Lowell B.B., and Flier J.S. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1 (1995) 1311-1314
42. Matsubara M., Maruoka S., and Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 147 (2002) 173-180
43. Li J., DeFea K., and Roth R.A. Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/phosphatidylinositol 3-kinase pathway. J Biol Chem 274 (1999) 9351-9356
44. Gual P., Gremeaux T., Gonzalez T., Le Marchand-Brustel Y., and Tanti J.F. MAP kinases and mTOR mediate insulin-induced phosphorylation of insulin receptor substrate-1 on serine residues 307, 612 and 632. Diabetologia 46 (2003) 1532-1542
45. Ueno M., Carvalheira J.B., Tambascia R.C., Bezerra R.M., Amaral M.E., Carneiro E.M., et al. Regulation of insulin signalling by hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway. Diabetologia 48 (2005) 506-518
46. Tremblay F., Gagnon A., Veilleux A., Sorisky A., and Marette A. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology 146 (2005) 1328-1337
47. Hennige A.M., Stefan N., Kapp K., Lehmann R., Weigert C., Beck A., et al. Leptin down-regulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1. FASEB J 20 (2006) 1206-1208
48. Berg C.E., Lavan B.E., and Rondinone C.M. Rapamycin partially prevents insulin resistance induced by chronic insulin treatment. Biochem Biophys Res Commun 293 (2002) 1021-1027
49. Haruta T., Uno T., Kawahara J., Takano A., Egawa K., Sharma P.M., et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 14 (2000) 783-794
50. Zhande R., Mitchell J.J., Wu J., and Sun X.J. Molecular mechanism of insulin-induced degradation of insulin receptor substrate 1. Mol Cell Biol 22 (2002) 1016-1026
51. Hartley D., and Cooper G.M. Role of mTOR in the degradation of IRS-1: regulation of PP2A activity. J Cell Biochem 85 (2002) 304-314
52. Tzatsos A., and Kandror K.V. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 26 1 (2006) 63-76
53. Shaw R.J., Bardeesy N., Manning B.D., Lopez L., Kosmatka M., DePinho R.A., et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6 (2004) 91-99
54. Hotamisligil G.S., Peraldi P., Budavari A., Ellis R., White M.F., and Spiegelman B.M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271 (1996) 665-668
55. Fain J.N. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 74 (2006) 443-477
56. Loffreda S., Yang S.Q., Lin H.Z., Karp C.L., Brengman M.L., Wang D.J., et al. Leptin regulates proinflammatory immune responses. FASEB J 12 (1998) 57-65
57. Zhao T., Hou M., Xia M., Wang Q., Zhu H., Xiao Y., et al. Globular adiponectin decreases leptin-induced tumor necrosis factor-alpha expression by murine macrophages: Involvement of cAMP-PKA and MAPK pathways. Cell Immunol 238 (2006) 19-30
58. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102 (2000) 1296-1301
59. Ouchi N., Kihara S., Arita Y., Maeda K., Kuriyama H., Okamoto Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
60. Kobashi C., Urakaze M., Kishida M., Kibayashi E., Kobayashi H., Kihara S., et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 97 (2005) 1245-1252
61. Kanety H., Feinstein R., Papa M.Z., Hemi R., and Karasik A. Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem 270 (1995) 23780-23784
62. Tsuchida A., Yamauchi T., Ito Y., Hada Y., Maki T., Takekawa S., et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 279 (2004) 30817-30822